Genprex (NASDAQ:GNPX) Announces Quarterly Earnings Results

Genprex (NASDAQ:GNPX) announced its quarterly earnings results on Wednesday. The company reported ($0.64) earnings per share for the quarter, Zacks reports.

Genprex Stock Up 2.5%

Shares of Genprex stock traded up $0.02 on Wednesday, reaching $0.85. The company’s stock had a trading volume of 178,655 shares, compared to its average volume of 1,280,452. The company has a market capitalization of $8.87 million, a P/E ratio of -0.03 and a beta of -0.94. Genprex has a 52-week low of $0.81 and a 52-week high of $55.00. The stock has a 50-day moving average price of $1.47 and a 200-day moving average price of $2.47.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP increased its position in shares of Genprex (NASDAQ:GNPX) by 11.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent filing with the SEC. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.